Department of Research and Development, Biohit Oyj, Helsinki, Finland.
Department of Clinical Research, Biohit Oyj, Helsinki, Finland;
Anticancer Res. 2021 Feb;41(2):811-819. doi: 10.21873/anticanres.14833.
BACKGROUND/AIM: The GastroPanel test (Biohit Oyj) is interpreted by the GastroSoft application distinguishing eight biomarker profiles, of which five profiles have a morphological equivalent in the Updated Sydney System (USS) classification of gastritis, and 3 others specify functional disorders of the stomach: 1) high acid output, 2) low acid output, and 3) effects of proton pump inhibitor (PPI) medication. This study evaluated the prevalence of these biomarker profiles in dyspeptic patients.
A cross-sectional study was designed to assess the point prevalence of these biomarker profiles in a random sample of 500 subjects derived from our archives of GastroPanel samples.
Reflux symptoms were reported by 35.2% and use of PPI medication by 36.8% of the study subjects. Biomarker profile 2 (high acid output) was the second most common GastroPanel profile in this cohort; 31.2%, second only (33.6%) to profile 1 (healthy stomach). Hp-infection was detected in 25.0% of the subjects. Profiles related to use of PPI (low acid output, PPI effect) were found in 7.4% of the cases. AG was uncommon, diagnosed in 14 patients only (2.8%).
These data are derived from the population with the highest frequency of dyspepsia, and the results might have widespread implications in diagnostic and screening practices.
背景/目的：GastroPanel 测试（Biohit Oyj）由 GastroSoft 应用程序进行解读，区分出八种生物标志物谱，其中五种谱与胃炎的更新悉尼系统（USS）分类具有形态学等效性，另外三种则指定了胃的功能障碍：1）高酸输出，2）低酸输出，3）质子泵抑制剂（PPI）药物的影响。本研究评估了这些生物标志物谱在消化不良患者中的流行情况。
设计了一项横断面研究，以评估从我们的 GastroPanel 样本档案中随机抽取的 500 名受试者中这些生物标志物谱的时点患病率。
研究对象中有 35.2%报告有反流症状，36.8%使用了 PPI 药物。生物标志物谱 2（高酸输出）是该队列中第二常见的 GastroPanel 谱；31.2%，仅次于谱 1（健康胃），为 33.6%。在 25.0%的受试者中检测到 Hp 感染。与使用 PPI 相关的谱（低酸输出、PPI 效应）在 7.4%的病例中发现。AG 很少见，仅诊断出 14 例（2.8%）。
这些数据来自于消化不良发生率最高的人群，其结果可能对诊断和筛查实践具有广泛的影响。
